Global Patent Index - EP 0636024 A1

EP 0636024 A1 19950201 - POTENTIATION OF ANTIMICROBIAL EFFECTS.

Title (en)

POTENTIATION OF ANTIMICROBIAL EFFECTS.

Title (de)

POTENZIERUNG VON ANTIMIKROBIELLEN WIRKUNGEN.

Title (fr)

POTENTIALISATION D'EFFETS ANTIMICROBIENS.

Publication

EP 0636024 A1 19950201 (EN)

Application

EP 93909105 A 19930331

Priority

  • SE 9300275 W 19930331
  • SE 9201187 A 19920414

Abstract (en)

[origin: WO9320812A1] An antimicrobial composition comprising an antimicrobially effective amount of a combination of: A) a monoglyceride of lauric acid, a monoglyceride of monomyristic acid or a mixture of these monoglycerides, and B) at least one chemical substance selected from the following group: i) local anaesthetics of the amide type; ii) carbamide; iii) antibacterial substances in the form of steroid antibiotics, imidazole derivatives or nitroimidazole derivatives, and iv) diols with 3 - 6 carbon atoms, and C) optionally, a conventional physiologically acceptable carrier and/or physiologically acceptable additives. A process for the preparation of this composition by heating (A) to the transition temperature of the lipid, adding (B), and optionally (C), and cooling the mixture to form a solid lipid crystal composition. Use of the composition for the preparation of a dermatological preparation for combatting bacteria and fungi or as a preservative additive in a cosmetic product, a food product, or a medical product.

IPC 1-7

A61K 31/23; A61K 31/165; A61K 31/17; A61K 31/415; A61K 31/045; A01N 37/02; A01N 47/28; A01N 43/50

IPC 8 full level

A01N 37/06 (2006.01); A01N 37/12 (2006.01); A01N 37/14 (2006.01); A01N 47/28 (2006.01); A61K 31/045 (2006.01); A61K 31/047 (2006.01); A61K 31/165 (2006.01); A61K 31/23 (2006.01); A61K 31/415 (2006.01); A61K 31/545 (2006.01); A61K 31/575 (2006.01); A61P 25/02 (2006.01); A61P 31/04 (2006.01)

CPC (source: EP US)

A01N 37/12 (2013.01 - EP US); A61K 31/23 (2013.01 - EP US); A61K 31/415 (2013.01 - EP US); A61K 31/575 (2013.01 - EP US); A61P 17/00 (2017.12 - EP); A61P 25/02 (2017.12 - EP); A61P 31/04 (2017.12 - EP)

C-Set (source: EP US)

  1. A61K 31/23 + A61K 31/165
  2. A61K 31/23 + A61K 31/045
  3. A61K 31/415 + A61K 31/23
  4. A61K 31/575 + A61K 31/23
  5. A01N 37/12 + A01N 61/00 + A01N 47/28 + A01N 49/00 + A01N 43/50 + A01N 37/44 + A01N 31/02
  6. A01N 37/12 + A01N 2300/00
  7. A61K 31/23 + A61K 2300/00
  8. A61K 31/415 + A61K 2300/00
  9. A61K 31/575 + A61K 2300/00

Citation (search report)

See references of WO 9320812A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9320812 A1 19931028; AT E181502 T1 19990715; AU 3963993 A 19931118; AU 677580 B2 19970501; CA 2118114 A1 19931028; CA 2118114 C 20030617; DE 69325450 D1 19990729; DE 69325450 T2 19991223; DK 0636024 T3 19991122; EP 0636024 A1 19950201; EP 0636024 B1 19990623; ES 2132230 T3 19990816; GR 3030999 T3 19991231; HK 1007923 A1 19990430; JP 4014114 B2 20071128; JP H07505880 A 19950629; NZ 251783 A 19960726; SE 500777 C2 19940829; SE 9201187 D0 19920414; SE 9201187 L 19931015; SG 52341 A1 19980928; US 5550145 A 19960827

DOCDB simple family (application)

SE 9300275 W 19930331; AT 93909105 T 19930331; AU 3963993 A 19930331; CA 2118114 A 19930331; DE 69325450 T 19930331; DK 93909105 T 19930331; EP 93909105 A 19930331; ES 93909105 T 19930331; GR 990402077 T 19990818; HK 98108909 A 19980706; JP 51822193 A 19930331; NZ 25178393 A 19930331; SE 9201187 A 19920414; SG 1996003104 A 19930331; US 30776394 A 19940927